Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 5.32bn |
Free float | 5.01bn |
P/E (TTM) | -- |
Market cap | 15.96m AUD |
EPS (TTM) | -0.0052 AUD |
Data delayed at least 15 minutes.
More ▼
Announcements
- Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
- Alterity Therapeutics to Present at MST Financial Webinar
- Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
- Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
- Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
- Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
More ▼